35 results about "Human Immunoglobulin G" patented technology

A stable liquid formulation includes a fusion protein having an Fc domain of a human immunoglobulin G (IgG), in particular, a protein in which an Fc domain of a human immunoglobulin G (IgG) and a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor are fused (e.g., aflibercept)). A composition for stabilizing a protein and a method for stabilizing a protein in which an Fc domain of an IgG and a soluble extracellular domain of a VEGF receptor are fused are disclosed. The present invention improves therapeutic effects on various ophthalmic diseases (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization and wet age-related macular degeneration, etc.) caused by abnormal angiogenesis, while pursuing stabilization of bioactivity through a stable liquid formulation suitable for intravitreal injection of an anti-VEGF-Fc fusion protein including aflibercept.

The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg / kg to 800 mg / kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and / or an anti-beta amyloid monoclonal antibody.

The invention relates to a human immunoglobulin G composition characterized in that the human immunoglobulin G concentration is at least 230 g / l, which is of use in particular for subcutaneous administration.

A method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, includes: mutating the human CH1γ1 domain from the antibody, to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting the human CH1γ1 domain by the CH1 domain from a human IgG2 (CH1γ2), IgG3 (CH1γ3) or IgG4 (CH1γ4); the antibody obtained by such method, includes a) a light chain including the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen; and ii) a human kappa (κ)Constant (CL) domain; and b) a heavy chain including the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from the antigen; ii) the CH2 and CH3 domains from a human IgG1; and iii) the CH1 domain from a human IgG1, mutated to restore pairing between CHI and CL domains.

The invention discloses a preparation method of a redox probe for marking an h-IGg (Human-Immunoglobulin G) impedance immunosensor. The preparation method comprises the following steps of: dropping an absolute ethyl alcohol solution containing beta-mercaptoethylamine into an absolute ethyl alcohol solution in which 3,5-dibromosalicylaldehyde is dissolved, performing water-bath heating, recrystallizing and drying in vacuum so as to obtain beta-mercaptoethylamine shrinkage 3,5-dibromosalicylaldehyde Schiff base; preparing the absolute ethyl alcohol and N,N-dimethylformamide into a mixture solvent in a volume ratio of 2:1, dropwise adding an N,N-dimethylformamide solution containing nickel acetate into the mixture solvent of the beta-mercaptoethylamine shrinkage 3,5-dibromosalicylaldehyde Schiff base, performing water-bath heating, recrystallizing and drying in vacuum so as to obtain a beta-mercaptoethylamine shrinkage 3,5-dibromosalicylaldehyde Schiff base complex; dissolving the beta-mercaptoethylamine shrinkage 3,5-dibromosalicylaldehyde Schiff base complex into the absolute ethyl alcohol, and further adding into nanogold sol. The redox probe is simple to prepare and has the advantages of low detection limit, good stability, good reproducibility and the like when being used for marking the h-IGg impedance immunosensor to detect the h-IGg content.

The invention studies a molecularly imprinted electrochemical sensor based on an electrode modified by an electro-copper-based MOFs sensitive film, and a preparation method and detection method thereof, belonging to the field of electrochemical sensing. The present invention selects the specific protein human immunoglobulin G (IgG) in serum as the research object, and successfully constructs a new type of high-sensitivity molecular imprinting electrode by combining nanocomposite materials, a new imprinting method, a new template processing idea and a new detection method. chemical sensor. First, copper-based MOFs were synthesized on the surface of glassy carbon electrode by electrodeposition to modify the electrode to improve conductivity and increase specific surface area, then chitosan and glutaraldehyde were sequentially modified to provide attachment sites for IgG, and then directly on the surface of the modified electrode A polymer film is formed by electropolymerization of pyrrole, and the template is finally eluted to obtain a molecularly imprinted polymer-modified electrode. The molecularly imprinted electrochemical sensor has high sensitivity and good selectivity, and has been successfully applied to the detection of target proteins in actual samples.

The present invention provides, among other aspects, methods for the treatment of Alzheimer's disease in a subject in need thereof, the method including administration of a therapeutically effective amount of a pooled human immunoglobulin G (IgG) composition to a subject with moderately severe Alzheimer's disease, a subject carrying an ApoE4 allele, or both, where the amount of pooled human IgG is from 300 mg / kg to 800 mg / kg body weight of the subject per two week period, and where the amount is administered in one or more doses during the two week period after initiation of a therapeutic regimen. Also provided, are methods for selecting a treatment regimen for a subject with Alzheimer's disease, including diagnosing the severity of the Alzheimer's disease, determining if the subject carries an APOE4 allele, or both, and assigning a treatment regimen including administration of pooled human immunoglobulin G and / or an anti-beta amyloid monoclonal antibody.

The invention discloses a nano antibody fusion protein which is formed by connecting an Fc segment of a human immunoglobulin G with a VHH antibody segment of camel anti-human TNFa. The invention also discloses a preparation method and application of the fusion protein. Compared with the prokaryotically-expressed TNFa nano antibody and the prokaryotically-expressed Fc-modified TNFa nano antibody, the nano antibody fusion protein disclosed by the invention has higher biological activity; the yeast expression anti-TNF-VHH-Fc protein forms a complete dimer form, and thus, has higher stability and antigen combination activity; the Fc segment of immunoglobulin is selected as a fusion segment, thereby avoiding the generation of side effect; and the invention has the advantages of high expression level and low cost, and can easily implement scale-up production.